SRPK1 (serine/arginine‐rich protein‐specific kinase 1), EZH2 (enhancer of zeste homolog 2), GDF15 (growth differentiation factor 15), EEF1A2 (eukaryotic translation elongation factor 1 alpha 2), and NRP1 (neuropilin 1) represent crucial targets in cancer therapy, particularly within the context of TGF‐β signaling pathways driving tumor progression. Here, NRP1 is linked to neoplasm.